Impact of post-remission therapy in patients aged 65-70 years with de novoacute myeloid leukemia: A comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria

Haematologica

Volumn 96, Issue 6, 2011, Pages 837-844

  Itzykson, Raphael ^a   Gardin, Claude ^b   Pautas, Cécile ^c   Thomas, Xavier ^d   Turlure, Pascal ^e   Raffoux, Emmanuel ^a   Terré, Christine ^f   Fenaux, Pierre ^b   Castaigne, Sylvie ^f   Dombret, Hervé ^a   Boissel, Nicolas ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e LIMOGES UNIVERSITY HOSPITAL   (France)

^f CENTRE HOSPITALIER DE VERSAILLES   (France)

Author keywords

Acute myeloid leukemia; Older patients; Post remission therapy

Indexed keywords

CYTARABINE; DAUNORUBICIN; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOGENETICS; FEMALE; HUMAN; INTENSIVE CARE; KARYOTYPE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; PROGNOSIS; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79958072848     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.036921     Document Type: Article

References (27)

1. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol. 2007;25(14):1908-15.
2. Kantarjian H, O'Brien S, Cortes J, Giles F, Faderl S, Jabbour E, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106(5):1090-8.
3. Rollig C, Thiede C, Gramatzki M, Aulitzky W, Bodenstein H, Bornhauser M, et al. A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood. 2010;116(6):971-8.
4. Wheatley K, Brookes CL, Howman AJ, Goldstone AH, Milligan DW, Prentice AG, et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol. 2009;145(5):598-605.
5. Malfuson JV, Etienne A, Turlure P, de Revel T, Thomas X, Contentin N, et al. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica. 2008;93 (12):1806-13.
6. Dombret H, Raffoux E, Gardin C. Acute myeloid leukemia in the elderly. Semin Oncol. 2008;35(4):430-8.
7. Lowenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361(13):1235-48.
8. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman PP, et al. Post - remission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard- dose cytarabine. Blood. 2001;98 (3): 548-53.
9. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98(5):1302-11.
10. Schlenk RF, Frohling S, Hartmann F, Fischer JT, Glasmacher A, Del Valle F, et al. Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment trial. Leu - kemia. 2006;20(4):748-50.
11. Derolf AR, Kristinsson SY, Andersson TM, Landgren O, Dickman PW, Bjorkholm M. Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood. 2009;113(16):3666-72.
12. Gardin C, Turlure P, Fagot T, Thomas X, Terre C, Contentin N, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood. 2007;109(12):5129-35.
13. Pautas C, Merabet F, Thomas X, Raffoux E, Gardin C, Corm S, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol. 2010;28(5):808-14.
14. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the Inter - national Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003; 21(24):4642-9.
15. Cytogenetic IISfH, Nomenclature). Guide - lines for cancer cytogenetics. In: Mitelman F (ed), Supplement to an International System for Human Cytogenetic Nomenclature. Basel: Karger, 1991:1-53.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-81.
17. Korn EL. Censoring distributions as a measure of follow-up in survival analysis. Stat Med. 1986;5(3):255-60.
18. Burnett AK, Milligan D, Goldstone A, Prentice A, McMullin MF, Dennis M, et al. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol. 2009;145(3):318-32.
19. Lowenberg B, Beck J, Graux C, van Putten W, Schouten HC, Verdonck LF, et al. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood. 115(13):2586-91.
20. Baer MR, George SL, Sanford BL, Stone RM, Marcucci G, Mayer RJ, et al. Treatment of older patients with de novo acute myeloid leukemia (AML) with one or more postremission chemotherapy courses: Analysis of four CALGB studies. J Clin Oncol (Meeting Abstracts). 2010;28 (15 suppl):6531.
21. Pautas C, Thomas X, Merabet F, Raffoux E, Bourhis JH, de Botton S, et al. Randomized comparison of standard induction with daunorubicin (DNR) for 3 days vs idarubicin (IDA) for 3 or 4 days in AML pts aged 50 to 70 and of maintenance with interleukin 2. Final analysis of the ALFA 9801 Study. ASH Annual Meeting Abstracts. 2007;110:162.
22. Haferlach C, Mecucci C, Schnittger S, Kohlmann A, Mancini M, Cuneo A, et al. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Blood. 2009;114(14):3024-32.
23. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909-18.
24. Becker H, Marcucci G, Maharry K, Radmacher MD, Mrozek K, Margeson D, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol. 2010;28(4):596-604.
25. Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med. 1995;332 (25): 1678-83.
26. Baer MR, George SL, Caligiuri MA, Sanford BL, Bothun SM, Mrozek K, et al. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. J Clin Oncol. 2008;26(30):4934-9.
27. Prebet T, Boissel N, Reutenauer S, Thomas X, Delaunay J, Cahn JY, et al. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup. J Clin Oncol. 2009;27(28):4747-53.